

Neal X Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9618755/publications.pdf>

Version: 2024-02-01

58
papers

2,484
citations

218677

26
h-index

197818

49
g-index

58
all docs

58
docs citations

58
times ranked

2895
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>Non-Additive</sc> Effects of Combined <sc>NOX1</sc>/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease- Mineral and Bone Disorder (<sc>CKD-MBD</sc>). JBMR Plus, 2022, 6, e10600.	2.7	2
2	Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease. Bone, 2022, 157, 116340.	2.9	7
3	Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease. Bone Reports, 2022, 16, 101174.	0.4	1
4	Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrology Dialysis Transplantation, 2022, 37, 1857-1867.	0.7	5
5	Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease. Bone, 2021, 143, 115632.	2.9	13
6	Age and sex effects on FGF23-mediated response to mild phosphate challenge. Bone, 2021, 146, 115885.	2.9	19
7	Skeletal muscle metabolic responses to physical activity are muscle type specific in a rat model of chronic kidney disease. Scientific Reports, 2021, 11, 9788.	3.3	2
8	Regulation of reactive oxygen species in the pathogenesis of matrix vesicles induced calcification of recipient vascular smooth muscle cells. Vascular Medicine, 2021, 26, 585-594.	1.5	9
9	Single-cell RNA sequencing of intramedullary canal tissue to improve methods for studying fracture repair biology. BioTechniques, 2021, 71, 431-438.	1.8	1
10	Predicting fracture healing with blood biomarkers: the potential to assess patient risk of fracture nonunion. Biomarkers, 2021, 26, 703-717.	1.9	5
11	Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. , 2020, 30, 4-10.		24
12	Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease- Mineral Bone Disorder. Journal of Bone and Mineral Research, 2020, 35, 333-342.	2.8	14
13	Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD. Journal of Bone and Mineral Research, 2020, 35, 608-617.	2.8	31
14	Adverse Effects of Autoclaved Diets on the Progression of Chronic Kidney Disease and Chronic Kidney Disease-Mineral Bone Disorder in Rats. American Journal of Nephrology, 2020, 51, 381-389.	3.1	4
15	N-acetylcysteine (NAC), an anti-oxidant, does not improve bone mechanical properties in a rat model of progressive chronic kidney disease-mineral bone disorder. PLoS ONE, 2020, 15, e0230379.	2.5	6
16	Title is missing!. , 2020, 15, e0230379.		0
17	Title is missing!. , 2020, 15, e0230379.		0
18	Title is missing!. , 2020, 15, e0230379.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0230379.		0
20	Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. <i>Bone</i> , 2019, 127, 419-426.	2.9	6
21	Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cyl+ rats. <i>Scientific Reports</i> , 2019, 9, 7936.	3.3	14
22	Time course of rapid bone loss and cortical porosity formation observed by longitudinal μ CT in a rat model of CKD. <i>Bone</i> , 2019, 125, 16-24.	2.9	27
23	Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways. <i>Kidney International</i> , 2018, 93, 343-354.	5.2	88
24	Effect of dietary phosphorus intake and age on intestinal phosphorus absorption efficiency and phosphorus balance in male rats. <i>PLoS ONE</i> , 2018, 13, e0207601.	2.5	14
25	Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E594-E604.	3.5	30
26	Skeletal vascular perfusion is altered in chronic kidney disease. <i>Bone Reports</i> , 2018, 8, 215-220.	0.4	3
27	Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0159411.	2.5	62
28	Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw274.	0.7	20
29	Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease. <i>Heart Rhythm</i> , 2016, 13, 1105-1112.	0.7	11
30	Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. <i>Kidney International</i> , 2016, 89, 95-104.	5.2	19
31	Differential miRNA Expression in Cells and Matrix Vesicles in Vascular Smooth Muscle Cells from Rats with Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0131589.	2.5	37
32	Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cyl+ rat model of progressive kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 31, gfv352.	0.7	16
33	Low Bone Turnover in Chronic Kidney Disease Is Associated with Decreased VEGF-A Expression and Osteoblast Differentiation. <i>American Journal of Nephrology</i> , 2015, 41, 464-473.	3.1	17
34	Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. <i>Bone</i> , 2015, 77, 50-56.	2.9	23
35	Pathophysiology of Vascular Calcification. <i>Current Osteoporosis Reports</i> , 2015, 13, 372-380.	3.6	83
36	Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 499-509.	2.8	103

#	ARTICLE	IF	CITATIONS
37	Treating Bone Quality in Chronic Kidney Disease. <i>FASEB Journal</i> , 2015, 29, 702.1.	0.5	0
38	Adipocyte induced arterial calcification is prevented with sodium thiosulfate. <i>Biochemical and Biophysical Research Communications</i> , 2014, 449, 151-156.	2.1	61
39	Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e99262.	2.5	40
40	Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2013, 37, 191-198.	3.1	35
41	Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD). <i>PLoS ONE</i> , 2013, 8, e64558.	2.5	106
42	Reducing parathyroid hormone is essential for correcting cortical bone deficiencies associated with chronic kidney disease. <i>FASEB Journal</i> , 2013, 27, 967.10.	0.5	0
43	Vascular Calcification: Pathophysiology and Risk Factors. <i>Current Hypertension Reports</i> , 2012, 14, 228-237.	3.5	150
44	Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 211-219.	3.1	76
45	The pathophysiology of early-stage chronic kidney disease—mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2672-2681.	2.8	82
46	Calcimimetics inhibit renal pathology in rodent nephronophthisis. <i>Kidney International</i> , 2011, 80, 612-619.	5.2	30
47	RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC). <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F674-F680.	2.7	29
48	Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. <i>Kidney International</i> , 2010, 77, 436-442.	5.2	51
49	A rat model of chronic kidney disease-mineral bone disorder. <i>Kidney International</i> , 2009, 75, 176-184.	5.2	136
50	Annexin-Mediated Matrix Vesicle Calcification in Vascular Smooth Muscle Cells. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1798-1805.	2.8	147
51	Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F599-F606.	2.7	55
52	Uremic Vascular Calcification. <i>Journal of Investigative Medicine</i> , 2006, 54, 380-384.	1.6	24
53	High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3435-3442.	0.7	159
54	Vascular calcification in chronic kidney disease. <i>Seminars in Nephrology</i> , 2004, 24, 61-68.	1.6	48

#	ARTICLE	IF	CITATIONS
55	Arterial calcification in diabetes. <i>Current Diabetes Reports</i> , 2003, 3, 28-32.	4.2	142
56	Fluid shear-induced NF κ B translocation in osteoblasts is mediated by intracellular calcium release. <i>Bone</i> , 2003, 33, 399-410.	2.9	83
57	Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. <i>Kidney International</i> , 2002, 62, 1724-1731.	5.2	297
58	The Role of the Synovium and Cartilage in the Pathogenesis of β 2-microglobulin Amyloidosis. <i>Seminars in Dialysis</i> , 2001, 14, 127-130.	1.3	17